<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5631339</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx180.009</article-id><article-id pub-id-type="publisher-id">ofx180.009</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Late Breaker Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>Week 48 Results of EMERALD: A&#x000a0;Phase 3, Randomized, Non-inferiority Study Evaluating the Efficacy and Safety of Switching from Boosted-protease Inhibitors (bPI) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Regimens to the Once Daily (QD), Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-infected Adults</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Orkin</surname><given-names>Chloe</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Molina</surname><given-names>Jean-Michel</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Gallant</surname><given-names>Joel</given-names></name><degrees>MD, MPH, FIDSA</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Negredo</surname><given-names>Eugenia</given-names></name><degrees>MD PhD</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Gathe</surname><given-names>Joseph</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Eron</surname><given-names>Joseph</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Van Landuyt</surname><given-names>Erika</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><name><surname>Lathouwers</surname><given-names>Erkki</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><name><surname>Hufkens</surname><given-names>Veerle</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><name><surname>Petrovic</surname><given-names>Romana</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><name><surname>Opsomer</surname><given-names>Magda</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><collab>EMERALD Study Group</collab><xref ref-type="aff" rid="AF0001">1</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>Barts Health NHS Trust</institution>, <addr-line>London</addr-line>, <country>UK</country>;</aff><aff id="AF0002">
<label>2</label>
<institution>Department of Infectious Diseases, Saint-Louis Hospital</institution>,, <addr-line>Paris</addr-line>, <country>France</country>;</aff><aff id="AF0003">
<label>3</label>
<institution>Southwest CARE Center</institution>, <addr-line>Santa Fe, New Mexico</addr-line>;</aff><aff id="AF0004">
<label>4</label>
<institution>Germans Trias i Pujol University Hospital</institution>, <addr-line>Badalona</addr-line>, <country>Spain</country>;</aff><aff id="AF0005">
<label>5</label>
<institution>Plaza Medical Center</institution>, <addr-line>Houston, Texas</addr-line>;</aff><aff id="AF0006">
<label>6</label>
<institution>University of North Carolina at Chapel Hill</institution>, <addr-line>Chapel Hill, North Carolina</addr-line>;</aff><aff id="AF0007">
<label>7</label>
<institution>Janssen Pharmaceutica NV</institution>, <addr-line>Beerse</addr-line>, <country>Belgium</country></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 188. HIV: Modern&#x000a0;ART</p><p>
<italic>Friday, October 6, 2017: 2:00 PM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S737</fpage><lpage>S738</lpage><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx180.009.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>EMERALD is evaluating the efficacy and safety of switching from bPI + FTC/TDF regimens (control) to D/C/F/TAF 800/150/200/10&#x000a0;mg in virologically suppressed, HIV-1-infected adults. We present Week 48 primary results.</p></sec><sec id="s2"><title>Method</title><p>EMERALD (NCT02269917) is a randomized, active-controlled, open-label, international, multicenter, parallel-group, non-inferiority trial. Virologically suppressed (viral load [VL] &#x0003c; 50 c/mL for &#x02265;2&#x000a0;months), HIV-1-infected adults were randomized (2:1) to switch to D/C/F/TAF or continue control. The FDA-stipulated primary endpoint was non-inferiority of D/C/F/TAF vs. control regarding % virologic rebound (confirmed VL &#x02265; 50 c/mL or premature discontinuations with last VL &#x02265; 50 c/mL) cumulative through Week 48 (4% margin).</p></sec><sec id="s3"><title>Result</title><p>1141 patients were randomized and treated (<italic>N =</italic> 763 D/C/F/TAF; <italic>N =</italic> 378 control); median age 46; 18% women; 76% white; 58% on &#x0003e;2 previous ARVs (prior to screening regimen); 15% with previous non-DRV virologic failure (VF). Virologic rebound through Week 48 was non-inferior for D/C/F/TAF (2.5%; <italic>n =</italic> 19)&#x000a0;vs. control (2.1%; <italic>n =</italic> 8)&#x000a0;(&#x00394;0.4%, 95% CI: &#x02013;1.5%; 2.2%; <italic>P &#x0003c;</italic> 0.001). Most rebounders (12/19 [63%] vs. 4/8 [50%]) resuppressed by Week 48 without change in therapy. Week 48 virologic suppression rates (VL &#x0003c; 50 c/mL; FDA Snapshot) were 94.9% vs. 93.7% (&#x00394;1.2%, 95% CI: &#x02212;1.7%;4.1%) and VF rates (VL &#x02265; 50 c/mL; Snapshot) were 0.8% vs. 0.5% (&#x00394;0.3%, 95% CI: &#x02212;0.7%;1.2%), with no discontinuations for VF. No resistance-associated mutations related to any study drug were observed.</p><p>Adverse events (AEs) were similar between arms: AE-related discontinuations (1.4% vs. 1.3%); grade 3&#x02013;4 AEs (6.8% vs. 8.2%); serious AEs (4.6% vs. 4.8%); and no deaths. Renal and bone parameters favored D/C/F/TAF vs. control. TC and LDL-C slightly favored control vs. D/C/F/TAF, with no clinically significant difference in TC/HDL-C ratio between arms (Table&#x000a0;1).</p></sec><sec id="s4"><title>Conclusion</title><p>Percentage of virologic rebound after switching to D/C/F/TAF was non-inferior to control cumulative through Week 48, with high suppression rates (94.9%), no resistance development, better bone and renal safety parameters and similar TC/HDL-C ratio. D/C/F/TAF maintains the high genetic barrier to resistance of darunavir with the safety advantages of TAF, even in patients with a history of non-DRV&#x000a0;VF.</p><fig fig-type="figure" id="F1" orientation="portrait" position="float"><label>Table&#x000a0;1:</label><caption><p>Changes from baseline at Week 48 in renal, lipid, and bone parameters</p></caption><graphic xlink:href="OFIDIS_ofx180_IF006"/></fig></sec><sec id="s5"><title>Disclosures</title><p>C.&#x000a0;Orkin, Janssen Pharmaceuticals: Grant Investigator, Scientific Advisor and Speaker&#x02019;s Bureau, Consulting fee, Research grant, Speaker honorarium and Travel bursary to attend conference. MSD: Grant Investigator, Scientific Advisor and Speaker&#x02019;s Bureau, Consulting fee, Research grant, Speaker honorarium and Travel bursary to attend conference. Viiv Healthcare: Grant Investigator, Scientific Advisor and Speaker&#x02019;s Bureau, Consulting fee, Research grant, Speaker honorarium and Travel bursary to attend conference. Gilead Sciences: Grant Investigator, Scientific Advisor and Speaker&#x02019;s Bureau, Consulting fee, Research grant, Speaker honorarium and Travel bursary to attend conference. J.&#x000a0;M. Molina, Merck / Gilead: Scientific Advisor, Research grant. Janssen / Viiv / BMS / Teva: Scientific Advisor, Speaker honorarium. Gilead: Speaker&#x02019;s Bureau, Speaker honorarium. J.&#x000a0;Gallant, Janssen Therapeutics: Investigator, Research support. E.&#x000a0;Negredo, Janssen: Board Member, Scientific Advisor and Speaker&#x02019;s Bureau, Speaker honorarium. J.&#x000a0;Gathe, Janssen: Consultant and Investigator, Research grant and Speaker honorarium. J.&#x000a0;Eron, Janssen: Consultant and Grant Investigator, Consulting fee and Grant recipient. E.&#x000a0;Van Landuyt, Janssen: Employee and Shareholder, Salary. E.&#x000a0;Lathouwers, Janssen: Employee and Shareholder, Salary. V.&#x000a0;Hufkens, Janssen: Employee and Shareholder, Salary. R.&#x000a0;Petrovic, Janssen: Employee and Shareholder, Salary. M.&#x000a0;Opsomer, Janssen: Employee and Shareholder, Salary.</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>